Jiangxi Rimag Group Past Earnings Performance
Past criteria checks 1/6
Jiangxi Rimag Group's earnings have been declining at an average annual rate of -76.3%, while the Healthcare industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 5.1% per year.
Key information
-76.3%
Earnings growth rate
-77.4%
EPS growth rate
| Healthcare Industry Growth | 11.3% |
| Revenue growth rate | -5.1% |
| Return on equity | -0.6% |
| Net Margin | 0.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jiangxi Rimag Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 813 | 5 | 293 | 13 |
| 31 Mar 24 | 871 | 25 | 278 | 13 |
| 31 Dec 23 | 929 | 44 | 264 | 13 |
| 31 Dec 22 | 784 | 0 | 197 | 11 |
| 31 Dec 21 | 592 | -361 | 477 | 12 |
Quality Earnings: 2522 has a large one-off gain of CN¥6.5M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 2522's current net profit margins (0.6%) are lower than last year (2.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2522 has become profitable over the past 5 years.
Accelerating Growth: 2522's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2522 had negative earnings growth (-76.3%) over the past year, making it difficult to compare to the Healthcare industry average (-16.9%).
Return on Equity
High ROE: 2522's Return on Equity (-0.6%) is considered low.